CD8A and neoplasm: Second, comprehensive pan-pathway immune landscape investigations identified MAPK-mutant tumors as the only “CD8+ T-cell–inflamed” tumors with inherently immunoreactive tumor microenvironments with constitutive cytolysis, subsequently validated in immunocompetent HNSCC models.